The novel circular RNA circ-CAMK2A enhances lung adenocarcinoma metastasis by regulating the miR-615-5p/fibronectin 1 pathway

Jiahui Du, Guangzhao Zhang, Hongli Qiu, Haifeng Yu and Wuying Yuan*

Abstract

Background: Circular RNA (circRNA) has recently been considered as a key regulator in carcinogenesis. In this study, we investigated the functional significance and regulatory role of circ-CAMK2A (hsa_circ_0128332) in lung adenocarcinoma (LUAD).

Methods: GSE101586 was employed to screen differentially expressed circRNAs. Relative expression levels of circ-CAMK2A, miR-615-5p, fibronectin 1 (FN1), MMP2, and MMP9 were tested by quantitative reverse transcription PCR (qRT-PCR) or western blotting. Functional experiments were performed by CCK-8, wound healing, and transwell assays. Luciferase reporter and biotin-labeled RNA pull-down assays were carried out to evaluate the interaction between circ-CAMK2A, miR-615-5p, and fibronectin 1. In addition, a lung metastasis model was constructed to determine the metastasis-promoting role of circ-CAMK2A in vivo.

Results: Circ-CAMK2A overexpression was observed in LUAD and was closely associated with lymph node metastasis, distant metastasis, advanced clinical stage, and poor prognosis. Circ-CAMK2A silencing evidently inhibited LUAD cell migration and invasion, whereas circ-CAMK2A overexpression had an opposite effect. Importantly, overexpression of circ-CAMK2A also enhanced LUAD metastasis in vivo. Mechanistically, miR-615-5p was identified as a direct target of circ-CAMK2A. Circ-CAMK2A up-regulates the expression level of fibronectin 1 by sponging miR-615-5p, thereby increasing MMP2 and MMP9 expression to promote the metastasis of LUAD.

Conclusion: Circ-CAMK2A plays a crucial role in the metastasis of LUAD, at least partially, by regulating the miR-615-5p/fibronectin 1 axis.

Keywords: Circular RNA, microRNA, Lung adenocarcinoma, Metastasis, Prognosis

Introduction

Lung adenocarcinoma (LUAD), accounting for about 40% of all lung cancer subtypes, is the most frequent cause of cancer-related deaths worldwide [1]. The average survival of patients with LUAD is very low, ranging from 4 to 17% [2]. Metastasis is primarily responsible for death from cancers, including LUAD [3, 4]. Therefore, it is extremely important to elucidate the potential molecular regulatory mechanisms of LUAD metastasis and to identify new metastatic markers, which will provide new options for the clinical treatment of metastatic LUAD patients.
Circular RNA (circRNA) has a covalent closed-loop structure and is highly stable and conservative [5]. Previously, these transcripts have been considered to be very rare in cells and have long been ignored [6]. This concept has changed with the development of high-throughput sequencing. Emerging evidence suggests that circRNAs are abundant in eukaryotes and exhibit a tissue- and developmental stage-specific expression manner [7, 8]. Recent studies showed that dysregulation of circRNA was involved in the occurrence and development of human diseases, including cancers [9]. For instance, down-regulation of circ-MTO1 was observed in hepatocellular carcinoma and linked to aggressive progression [10]. Circ-SFMBT2 was increased in gastric cancer and promoted cell proliferation [11]. Zeng et al. showed that circ-ANKS1B was notably elevated in breast cancer and contributed to breast cancer metastasis [12]. Similarly, circRNA dysregulation was also identified in LUAD, such as has_circ_0006427, hsa_circ_0000729, circRNA_102231 and F-circEA [13–17], implying that circRNAs play important roles in LUAD pathogenesis.

Here, we describe a dysregulated circRNA circ-CAMK2A (hsa_circ_0128333) in LUAD derived from back-splice junction of CAMK2A exons 16 and 17. We also investigated its clinical significance and biological function.

Materials and methods

LUAD tissues and cell lines

The protocols were approved by the Ethics Committee of Henan Provincial Chest Hospital and were performed in accordance with the ethical standards outlined in the 1964 Declaration of Helsinki and its later amendments. We collected 58 pairs of fresh frozen LUAD and para-carcinoma tissues from Henan Provincial Chest Hospital, which were quickly stored at −80 °C for RNA protection. LUAD cell lines including NCI-H1299, NCI-H1975, HCC827, NCI-H23, A549, SPC-A1 and one normal HBE cell line were all grown in RPMI1640 or DMEM medium as described previously [18]. A mycoplasma test was performed on each cell line before use.

Quantitative reverse transcription PCR (qRT-PCR)

The RNAsimple kit from TIANGEN (Beijing, China) was used to collect total RNA, followed by cDNA synthesis with 1 μg of RNA and RNA amplification and quantification. DNase I (Sangon Biotech, Shanghai, China) was employed to exclude gDNA contamination before reverse transcription. The 2^\(-\Delta\Delta Ct\) method was employed to calculate gene relative expression. The primer sequences were as follows: circ-CAMK2A: Forward: 5’-TGACAGCCTTCGAACCTGAG-3’, Reverse: 5’-TCCATTGCTTATGGCTTCAA-3’; FN1: Forward: 5’-AGCCGAGGTTTTAACTGCGA-3’, Reverse: 5’-CCCCACTCGGTGTAAGTGTCCCC-3’; MMP2: Forward: 5’-CCACTGCTCTGCTCTGCT-3’, Reverse: 5’-GTCCCGGAGTGAGTTGA-3’; ACTB: Forward: 5’-CGTACCCTGCGCATCGTGAT-3’, Reverse: 5’-GTGTTGCGCTACAGGTCTTTG-3’;
Cell transfection
Small interfering RNA targeting circ-CAMK2A (si-circ-CAMK2A) or fibronectin 1 (si-FN1), miR-615-5p mimics and inhibitors were all purchased from Gene-Pharma (Shanghai, China). The above oligonucleotides including 50 nM si-circ-CAMK2A (5′-AAACCTGGGAAACAGGAAAT-3′), miR-615-5p mimics (sense: 5′-GGGGGUCCCCGGUGCUCCGAUC-3′; anti-sense: 5′-UCCGAGACCCGGGGACCCCUU-3′) or inhibitors (5′-GATCCGAGCACCGGGGACCCCA-3′) and 1 μg of circ-CAMK2A-overexpressing pLO-ciR vector (Geneseed, Guangzhou, China) vectors were alone or in combination transfected into A549 and HCC827 LUAD cell lines with a 60–70% confluence using Lipofectamine 3000 (Invitrogen, Waltham, MA, USA). After 48 h of transfection, cells were collected for detection of transfection efficiency and subsequent experiments.

Cell counting Kit-8 (CCK-8) assay
A549 and HCC827 cells were seeded into 96-well plates. After the indicated time (0 h, 24 h, 48 h, and 72 h), the cells in each well were treated with 10 μl of CCK-8 reagent (Houston, TX, USA) for 1-4 h at 37 °C, followed by detection of 450 nm absorbance.

Wound healing and transwell assays
Cell migration ability was tested by wound healing assay. Briefly, A549 and HCC827 cells were cultured in 6-well plates with serum-free DMEM medium. Then, scratches were generated with sterile pipette tips. 48 h later, scratches in each well were photographed and their area was analyzed with Image J software. For the cell invasion assay, A549 and HCC827 cells were placed into 24-well transwell chambers with Matrigel. After 24 h of incubation, the invasive cells on the lower surface were stained with crystal violet and analyzed using an inverted microscope (magnification× 100, Olympus, Japan).

Lung metastasis model
5 × 10⁵ transfected A549 or HCC827 cells were injected into nude mice through the tail vein (n = 6 for each group), and then the nude mice were routinely raised. After 5 weeks, the nude mice were euthanized. Their lungs were removed surgically and subjected to H&E staining. The number of lung metastatic nodules in each group was counted.

Luciferase reporter assay
The recombination luciferase plasmids containing circ-CAMK2A or fibronectin 1 full-length sequences were respectively obtained (Genecopoeia, Rockville, Md, USA), followed by transfection in combination with miR-615-5p mimics into A549 and HCC827 cells by Lipofectamine 3000 (Invitrogen). After 48 h of treatment, the luciferase activity was measured.

RNA pull-down assay
Briefly, the biotinylated control (5′-GCTAAAGTCAAGTCTGAAAAGCAATGTGTGTCCTCAGTG-3′), circ-CAMK2A (5′-TTGAAACCTTGCGGAAAACAGGTTGTCCTCAGTG-3′) and miR-615-5p (5′-GATCCGAGACCCGGGGACCCCA-3′) probes were obtained from Gene-Pharma (Shanghai, China) and then incubated with streptavidin magnetic beads (BioMag, Shanghai, China) for 1 h at room temperature. Next, the lysates from A549
and HCC827 cells were incubated with probe-bound magnetic beads overnight at 4 °C. Lastly, the pulled-down RNA was extracted by Trizol reagent, followed by qRT-PCR analysis.

**Western blotting and immunohistochemistry (IHC)**

The lysates from A549 and HCC827 cells were collected by RIPA buffer. After that, a total of 20 μg of protein was transferred onto PVDF membrane, followed by incubation with anti-MMP2 (1/5000 dilution, #ab2462, Abcam), anti-MMP9 (1/2000 dilution, #ab76003, Abcam), anti-fibronectin 1 (1/8000 dilution, #ab181602, Abcam), and anti-GAPDH (1/10000 dilution, #ab181602, Abcam) at 4 °C overnight. The next day, the membrane was washed strictly and probed with secondary antibody and visualized. IHC was performed in tissue microarrays (TMA) containing 58 LUAD tissue samples using anti-fibronectin 1 (1/500 dilution, #ab23750, Abcam).

**Statistical analysis**

All statistical analysis was performed using SPSS or GraphPad Prism 5 software. The differences between two groups were analyzed using Student’s t or chi-square test. Kaplan–Meier plot was used to analyze the overall survival in LUAD patients. The correlation between circ-CAMK2A and miR-615-5p expression was analyzed using Pearson’s correlation test.

**Results**

**Circ-CAMK2A is identified to be significantly upregulated in LUAD and indicates poor prognosis**

First, we analyzed the GSE101586 data concerning 5 pairs of LUAD and adjacent non-cancer tissues (https://www.ncbi.nlm.nih.gov/geo) in order to find key circRNAs that are dysregulated in LUAD. As shown in Fig. 1a, the expression of circ-CAMK2A (hsa_circ_0128333) displayed the greatest fold change, which was markedly increased in LUAD. Then, we downloaded the sequence of circ-CAMK2A from circBase (http://www.circbase.org/) and found that it was derived from the back splicing of exons 16 and 17 of the linear CAMK2A gene (full length is 171 bp) (Fig. 1b). Further, circ-CAMK2A was also found to be significantly upregulated in LUAD tissues collected by us when compared with matched normal tissues (Fig. 1c, Additional file 1: Figure S1). Similar results were also observed in LUAD cell lines (Fig. 1d). Of note, increased circ-CAMK2A expression was closely associated with lymph node metastasis (P = 0.001), distant metastasis (P = 0.01), advanced TNM stage (P = 0.017) (Table 1) and unfavorable outcome (P = 0.012). Cox multivariate analysis showed that circ-CAMK2A was an independent risk prognostic factor for overall survival of LUAD patients (Table 2).

**Circ-CAMK2A contributes to LUAD migration, invasion, and metastasis in vitro and in vivo**

Since the circ-CAMK2A expression in A549 and HCC827 cells is the lowest and highest, respectively, we chose A549 cells for circ-CAMK2A overexpression and HCC827 cells for circ-CAMK2A silencing. As shown in Fig. 2a, the efficiency of
over-expressing or knocking down circ-CAMK2A was verified by qRT-PCR. Manipulating the expression of circ-CAMK2A had no effect on CAMK2A expression (Additional file 1: Figure S2). The results of the CCK-8 proliferation assay indicated that circ-CAMK2A ectopic expression or knockdown had no effect on cell proliferative capacity (Fig. 2b). However, overexpression of circ-CAMK2A increased, but depletion of circ-CAMK2A decreased, the ability of LUAD cells to migrate and invade (Fig. 2c-e). Moreover, the lung metastasis model was established. The results showed that more lung metastasis nodules were identified in circ-CAMK2A-overexpressing nude mice than in control nude mice (Fig. 2f). By contrast, silencing of circ-CAMK2A significantly impeded in vivo lung metastasis (Fig. 2g).

**Circ-CAMK2A directly binds to miR-615-5p**

The nuclear and cytoplasmic qRT-PCR and FISH results showed that circ-CAMK2A was predominately located in the cytoplasm (Fig. 3a, b), and RIP results showed that circ-CAMK2A was abundantly enriched by Ago2 (Additional file 1: Figure S3), suggesting that circ-CAMK2A may function as a microRNA sponge [19]. By analyzing the online RegRNA 2.0 software (http://regrna2.mbc.nctu.edu.tw/), we found three potential
miR-615-5p binding sites on circ-CAMK2A, as shown in Fig. 3c and d. Further, the results of the luciferase reporter assay showed that miR-615-5p dramatically reduced the luciferase activity of wild-type circ-CAMK2A vector, but did not affect the mutant one (Fig. 3e). To investigate whether circ-CAMK2A and miR-615-5p directly interact, we conducted the RNA pull-down assay. The results showed that more miR-615-5p was enriched in A549 and HCC827 cells by the circ-CAMK2A probe as compared to the control oligo probe (Fig. 3f), suggesting that circ-CAMK2A could directly bind to miR-615-5p. In addition, miR-615-5p was significantly downregulated in LUAD tissues and cell lines (Fig. 3g, h). Overexpression of miR-615-5p inhibited, whereas depletion of miR-615-5p promoted, LUAD cell migration and invasion (Fig. 3i). Overexpression and silencing of circ-CAMK2A

### Table 1 Correlation between circ-CAMK2A expression and clinicopathological features in LUAD patients

| Parameters                      | All cases | circ-CAMK2A expression |   |   |
|---------------------------------|-----------|------------------------|---|---|
|                                 |           | Low        | High   |   |   |
| Gender                          |           |            |         |   |   |
| Male                            | 34        | 15         | 19      |   | 0.286 |
| Female                          | 24        | 14         | 10      |   |   |
| Age (years)                     |           |            |         |   |   |
| ≤ 65                            | 26        | 11         | 15      |   | 0.291 |
| > 65                            | 32        | 18         | 14      |   |   |
| Tumor size                      |           |            |         |   |   |
| ≤ 3                             | 21        | 13         | 8       |   | 0.172 |
| > 3                             | 37        | 16         | 21      |   |   |
| Lymph node metastasis           |           |            |         |   |   |
| No                              | 27        | 20         | 7       |   | 0.001 |
| Yes                             | 31        | 9          | 22      |   |   |
| p-TNM stage                     |           |            |         |   |   |
| I-II                            | 33        | 21         | 12      |   | 0.017 |
| III-IV                          | 25        | 8          | 17      |   |   |
| Distant metastasis              |           |            |         |   |   |
| No                              | 46        | 27         | 19      |   | 0.01 |
| Yes                             | 12        | 2          | 10      |   |   |

### Table 2 Uni- and multivariate analysis of prognostic predictors for overall survival in NSCLC patients (n = 58)

| Variable                      | Univariate analysis | Multivariate analysis |
|-------------------------------|---------------------|-----------------------|
|                               | HR (95% CI) | P value | HR (95% CI) | P value |
| Gender                        | 1.086 (0.586–1.135) | 0.735 |             |         |
| Age                           | 1.134 (0.742–2.035) | 0.614 |             |         |
| Tumor size                    | 2.156 (1.168–4.986) | 0.022 | 1.354 (0.478–2.861) | 0.372 |
| Lymph node metastasis         | 3.612 (1.974–6.023) | 0.005 | 3.024 (1.586–5.466) | 0.016 |
| p-TNM stage                   | 4.311 (2.238–8.673) | 0.002 | 3.547 (2.067–6.331) | 0.009 |
| Distant metastasis            | 1.572 (1.385–3.996) | 0.038 | 1.151 (0.831–1.508) | 0.117 |
| Circ-CAMK2A expression        | 4.643 (2.275–9.031) | 0.001 | 3.941 (2.124–7.864) | 0.007 |
reduced and elevated the expression level of miR-615-5p, respectively (Fig. 3j). Similarly, silencing of miR-615-5p significantly increased circ-CAMK2A expression (Additional file 1: Figure S4). More importantly, a significant negative correlation between circ-CAMK2A and miR-615-5p expression was identified in LUAD tissues ($r = -0.702, P < 0.001$) (Fig. 3k).

**Fibronectin 1 is a direct target gene of miR-615-5p**

Through analyzing the online miRanda software (http://www.microrna.org/), a potential miR-615-5p binding site (GUGGACC) was observed on fibronectin 1
3′-UTR (Fig. 4a). The luciferase reporter assay in A549 and HCC827 cells showed that miR-615-5p overexpression dramatically decreased the luciferase activity of fibronectin 1 3′-UTR luciferase vector (Fig. 4b, c). Likewise, RNA pull-down assay indicated that miR-615-5p could directly interact with fibronectin 1 3′-UTR (Fig. 4d). Fibronectin 1 expression was found to be notably elevated in LUAD tissues (Fig. 4e) and miR-615-5p overexpression in HCC827 cells decreased, but miR-615-5p knockdown in A549 cells increased, the expression of fibronectin 1, as well as MMP2 and MMP9 (two important downstream genes of fibronectin 1) (Fig. 4f-h, Additional file 1: Figure S5). There data show that fibronectin 1 is regulated by miR-615-5p in LUAD cell lines.
Circ-CAMK2A promotes LUAD metastasis by the miR-615-5p/fibronectin 1 axis

To determine whether the circ-CAMK2A/miR-615-5p/fibronectin 1 regulatory pathway is present in LUAD, a series of assays were performed. We found that ectopic expression of circ-CAMK2A remarkably increased both mRNA and protein expression of fibronectin 1, MMP2 and MMP9 in A549 cells (Fig. 5a, b). Nevertheless, this upregulation effect was blocked by miR-615-5p overexpression (Fig. 5a, b). Conversely, silencing of circ-CAMK2A in HCC827 cells dramatically decreased fibronectin 1, MMP2 and MMP9 expression, and this effect was effectively rescued by miR-615-5p knockdown (Fig. 5c, d).

In addition, circ-CAMK2A expression in LUAD tissues was strongly positively linked to fibronectin 1 expression ($r = 0.762, P < 0.001$) (Fig. 5e, f). Importantly, miR-615-5p overexpression or fibronectin 1 knockdown could abolish circ-CAMK2A-induced increased...
migratory and invasive capability, as determined by wound healing and transwell assays (Fig. 5g), and vice versa (Fig. 5h). To sum up, these results suggest that increased circ-CAMK2A in LUAD reduces the activity of miR-615-5p to increase fibronectin 1 expression, thereby elevating MMP2 and MMP9 expression, and finally promoting LUAD metastasis (Fig. 5i).

**Discussion**

In the present study, we characterized a novel circRNA circ-CAMK2A originating from the back splicing of exons 16 and 17 of the linear CAMK2A gene that was markedly
overexpressed in LUAD tissues and cell lines and closely correlated with malignant features and an unfavorable outcome. Subsequent functional experiments showed that circ-CAMK2A strengthened the capability of LUAD cells to invade and migrate in vitro and in vivo without affecting proliferation. Mechanistically, circ-CAMK2A reduced miR-615-5p-mediated repression of fibronectin 1, resulting in increased MMP2 and MMP9 expression, thereby facilitating the metastasis of LUAD. Thus, these data uncover the essential functional and clinical implications of circ-CAMK2A in LUAD metastasis.

The field of circRNA is receiving great attention [20, 21]. Numerous studies reveal that the functional “microRNA sponge” model of circRNAs plays an important role in cancer [22]. For instance, circ-DENND2A effectively sponged miR-625-5p and promoted glioma aggressiveness [23]. Circ-HIPK3 contributed to colorectal cancer growth and metastasis by abundantly sponging miR-7 [24]. Here, circ-CAMK2A could also function via microRNA, in which one circ-CAMK2A was able to absorb three miR-615-5p and inhibited its expression level. miR-615-5p has been reported as a tumor suppressor in various human cancers, including pancreatic ductal adenocarcinoma [25], hepatocellular carcinoma [26] and esophageal squamous cell carcinoma [27]. Likewise, our data also confirmed that miR-615-5p was dramatically downregulated in LUAD. Thus, circ-CAMK2A exerts the metastasis-promoting role mainly by binding and inhibiting miR-615-5p.

microRNA could bind to the 3′-UTR of its downstream target gene to repress mRNA expression [28]. In the current study, it was found that miR-615-5p could directly interact with the 3′-UTR of fibronectin 1 mRNA to suppress fibronectin 1 expression. Fibronectin 1, an extracellular matrix glycoprotein, was proposed to be a vital mediator of metastasis in various cancers by activating the well-known pro-metastasis MMP2 and MMP9 genes [29]. Consistently, we observed that overexpression of circ-CAMK2A could notably increase fibronectin 1, MMP2, and MMP9 expression to enhance the migratory/invasive capacity of LUAD cells. Importantly, the above pro-metastasis effect was obviously abrogated by miR-615-5p overexpression and vice versa, implying that the regulatory network of circ-CAMK2A/miR-615-5p/fibronectin 1 does exist and plays an essential role in LUAD metastasis.

CircRNA has been emerging as a promising cancer biomarker [30]. For example, circ-0000502, circ-PRMT5, circ-SPINK1, circ-0103552 and ciRS-7 were reported to be promising prognostic biomarkers in osteosarcoma [31], bladder cancer [32], hepatocellular carcinoma [33], breast cancer [34] and colorectal cancer [35], respectively. Herein, we found that the survival time of LUAD patients with high circ-CAMK2A expression was obviously shortened, suggesting that circ-CAMK2A may be a potential prognostic biomarker of LUAD patients.

Conclusions
Our study clearly demonstrates that circ-CAMK2A is an oncogenic circRNA that facilitates the metastasis of LUAD mainly by the miR-615-5p/fibronectin 1 pathway, implying its potential as a prognostic indicator and druggable target for LUAD patients with metastasis.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s11658-019-0198-1.

Additional file 1 Figure S1. Northern blot analysis of circ-CAMK2A expression in three pairs of LUAD and normal tissues. 18S was used as control reference. Figure S2. qRT-PCR analysis of CAMK2A expression in LUAD cells with circ-CAMK2A overexpression or knockdown. Figure S3. RIP assay detecting the enrichment of circ-CAMK2A by Ago2 in HCC827 cells. **p < 0.01. Figure S4. The effect of miR-615-5p on circ-CAMK2A expression, qRT-PCR analysis of circ-CAMK2A expression in A549 cell lines transfected with control or miR-615-5p inhibitors. **p < 0.01. Figure S5. The protein quantification of FN1, MMP2 and MMP9 in LUAD cell lines with miR-615-5p knockdown or overexpression. **p < 0.01.

Abbreviations
CCK-8: Cell Counting Kit-8; circRNA: circular RNA; FN1: Fibronectin 1; IHC: Immunohistochemistry; LUAD: Lung adenocarcinoma; qRT-PCR: quantitative reverse transcription PCR

Acknowledgments
Not applicable.

Authors’ contributions
WYY designed and drafted this paper; JHD, GZZ and HLQ performed the experiments; JHD and HFY analyzed the data. All authors read and approved the final manuscript.

Funding
The present study was supported by The Science and Technology Project of Henan Province (grant nos. 2016023).

Availability of data and materials
Data available on request due to privacy/ethical restrictions.

Ethics approval and consent to participate
This research was carried out in accordance with the guidelines of the Ethics Committee of Henan Provincial Chest Hospital (acceptance no.: EC-2018-HY-005). Written informed consent was obtained from each participant. All protocols in the animal study were in accordance with the guidelines of the Institutional Animal Care and Use Committee review board of Henan Provincial Chest Hospital (acceptance no.: ZYXK20180011). Both of them were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Consent for publication
All authors approved publication of the manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 5 July 2019 Accepted: 16 December 2019
Published online: 26 December 2019

References
1. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543–50.
2. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311.
3. Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19(9):31.
4. Xie L, Chen Y, Chen J, Zhang H, Liao Y, Zhou Y, et al. Anti-tumor effects and mechanism of GA-13315, a novel gibberellin derivative, in human lung adenocarcinoma: an in vitro and in vivo study. Cell Mol Biol Lett. 2019;24:6.
5. Rybak-Wolf A, Strotmeister C, Glazar P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58:870–85.
6. Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976;73:3852–6.
7. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.
8. Hansen TB, Jensen TI, Clausen BH, Branssen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–8.
9. Jiang F, Shen X. Current prevalence status of gastric cancer and recent studies on the roles of circular RNAs and methods used to investigate circular RNAs. Cell Mol Biol Lett. 2019;24:53.
10. Han D, Li J, Wang H, Su X, Hou J, Gu Y, et al. Circular RNA circMDT1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. H epatol ogy. 2017;66:1151–64.
11. Sun H, Xi P, Sun Z, Wang Q, Zhu B, Zhou J, et al. Circ-SFMBT2 promotes the proliferation of gastric cancer cells through sponging miR-182-5p to enhance CREB1 expression. Cancer Manag Res. 2018;10:5725–34.
12. Zeng K, He B, Yang BB, Xu T, Chen X, Xu M, et al. The pro-metastasis effect of circANKS1B in breast cancer. Mol Cancer. 2018;17:160.
13. Yao Y, Hua Q, Zhou Y. CircRNA has_circ_0006427 suppresses the progression of lung adenocarcinoma by regulating miR-6783-3p/DKK1 axis and inactivating Wnt/beta-catenin signaling pathway. Biochem Biophys Res Commun. 2019;508:37–45.

14. Li S, Sun X, Miao S, Lu T, Wang Y, Liu J, et al. hsa_circ_0000729, a potential prognostic biomarker in lung adenocarcinoma. Thorac. Cancer. 2018;9:224–30.

15. Zong L, Sun Q, Zhang H, Chen Z, Deng Y, Li D, et al. Increased expression of circRNA_102231 in lung cancer and its clinical significance. Biomed Pharmacother. 2018;102:639–44.

16. Tan S, Sun D, Pu W, Gou Q, Guo C, Gong Y, et al. Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer. Mol Cancer. 2018;17:138.

17. Tan S, Gou Q, Pu W, Guo C, Yang Y, Wu K, et al. Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer. Cell Res. 2018;28:693–5.

18. Pang B, Wu N, Guan R, Pang L, Li X, Li S, et al. Overexpression of RCC2 enhances cell motility and promotes tumor metastasis in lung adenocarcinoma by inducing epithelial-Mesenchymal transition. Clin Cancer Res. 2017;23:5598–610.

19. Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong F, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17:79.

20. Shang Q, Yang Z, Jia R, Ge S. The novel roles of circRNAs in human cancer. Mol Cancer. 2019;18:6.

21. Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71:428–42.

22. Kristensen LS, Hansen TB, Veno MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37:555–65.

23. Su H, Zou D, Sun Y, Dai Y. Hypoxia-associated circDENND2A promotes glioma aggressiveness by sponging miR-625-5p. Cell Mol Biol Lett. 2019;24:24.

24. Zeng K, Chen X, Xu M, Liu X, Hu X, Xu T, et al. CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. Cell Death Dis. 2018;9:417.

25. Gao W, Gu Y, Li Z, Cai H, Peng Q, Tu M, et al. miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Oncogene. 2015;34:1629–40.

26. Wu X, Deng L, Tang D, Ying G, Yao X, Liu F, et al. miR-615-5p prevents proliferation and migration through negatively regulating serine hydromethyltransferase 2 (SHMT2) in hepatocellular carcinoma. Tumour Biol. 2016;37:6813–21.

27. Yang B, Xie R, Wu SN, Gao CC, Yang X, Zhou JF. MicroRNA-615-5p targets insulin-like growth factor 2 and exerts tumor-suppressing functions in human esophageal squamous cell carcinoma. Oncol Rep. 2018;39:255–63.

28. Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 2016;17:719–32.

29. Xu TP, Huang MD, Xia R, Liu XX, Sun M, Yin L, et al. Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin 1 expression. J Hematol Oncol. 2014;7:63.

30. Arnaiz E, Sole C, Manterola L, Iparraguirre L, Otaegui D, Lawrie CH. CircRNAs and cancer: biomarkers and master regulators. Semin Cancer Biol. 2018;58:90–9.

31. Qi H, Sun Y, Jiang Y, Li X. Upregulation of circular RNA circ_0000502 predicts unfavorable prognosis in osteosarcoma and facilitates cell progression via sponging miR-1238. J Cell Biochem. 2018. [Epub ahead of print]

32. Chen X, Chen RX, Wei WS, Li YH, Feng ZH, Tan L, et al. PRMT5 circular RNA promotes metastasis of Urothelial carcinoma of the bladder through sponging miR-30c to induce epithelial-Mesenchymal transition. Clin Cancer Res. 2018;24:6319–30.

33. Chen D, Zhang C, Lin J, Sun Y, Wang H. Screening differential circular RNA expression profiles reveal that hsa_circ_0128298 is a biomarker in the diagnosis and prognosis of hepatocellular carcinoma. Cancer Manag Res. 2018;10:1275–83.

34. Yang L, Song C, Chen Y, Jing G, Sun J. Circular RNA circ_0123552 forecasts dismal prognosis and promotes breast cancer cell proliferation and invasion by sponging miR-1236. J Cell Biochem. 2019. [Epub ahead of print]

35. Weng W, Wei Q, Toden S, Yoshida K, Nagasaka T, Fujibara T, et al. Circular RNA cirs-7-a promising prognostic biomarker and a potential therapeutic target in colorectal Cancer. Clin Cancer Res. 2017;23:3918–28.